MYGN Stock Recent News

Myriad's MyRisk®  test is the first hereditary cancer test integrated into Flatiron's OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, a leading health tech company dedicated to expanding the possibilities of point of care solutions in oncology. This collaboration allows physicians to order Myriad's MyRisk®  Hereditary Cancer Test and view the results of the test directly in Flatiron's cloud-based Electronic Medical Record (EMR) platform, OncoEMR®.

Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.

SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad's Precise® MRD test.

SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad's ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco.

SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.

MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences.

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President-Investor Relations Paul Diaz - President & Chief Executive Officer Mark Verratti - Chief Commercial Officer Sam Raha - Chief Operating Officer Scott Leffler - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Colleen Babington - Wolfe Research Andrew Cooper - Raymond James Casey Woodring - JPMorgan Puneet Souda - Leerink Partners Kyle Boucher - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics Second Quarter 2024 Financial Earnings Conference Call.